Ethypharm announces today that it has entered into a definitive agreement to acquire Altan Pharma, a specialty pharmaceutical company that develops, manufactures, and markets injectable medicines for hospital use.
Thanks to the strong presence of Altan Pharma in Spain, Ethypharm will reach full commercial coverage of the top 5 European markets upon closing, which is expected in the second half of 2021. Ethypharm will also benefit from an enlarged portfolio of high-quality hospital injectable products and a rich pipeline of R&D projects, which fit perfectly with its existing Critical Care franchise.
“Altan Pharma’s product portfolio and geographic coverage are highly complementary to those of Ethypharm. We look forward to welcoming Altan Pharma’s teams, as we are convinced that together, our product portfolio, our R&D, and our industrial expertise, will put us in a stronger position to fulfill our commitment to the patients we serve”, said Bertrand Deluard, CEO of Ethypharm. “The Altan Pharma acquisition is an important milestone in Ethypharm’s transformation journey. By entering the Spanish market and reinforcing our Critical Care franchise, Ethypharm proves once again its ability to execute on its long-term growth ambition.”
“Joining an established European specialty pharmaceutical company, with a strong direct commercial presence in Europe beyond Spain and in major growth territories for injectable medicines, will be a booster for the international expansion of Altan Pharma’s product portfolio,” said Guillermo Herrera, CEO of Altan Pharma. “Since its inception in 1998, Altan Pharma has been committed to improving patient care by providing specialty medications of superior quality and value for the benefit of patients and caregivers.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Jefferies International Limited acted as sole financial adviser to Altan Pharma on the transaction.
Source: Biospace
